Predicting successful weaning from continuous renal replacement therapy in acute kidney injury patients

PREdiction of succeSSful weanING From Continuous Renal Replacement Theraphy: the Possible Role of Delta C-cistatin

This study is testing if changes in a specific blood marker can help doctors know the best time to stop kidney support treatment in patients with acute kidney injury.

Quick facts

• Study type: Observational
• Enrollment: 152 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna (other)
• Locations: 2 sites (Bologna and 1 other locations)
• Trial ID: NCT06714214 on ClinicalTrials.gov

What this trial studies

This observational study aims to determine if changes in plasma concentration of c-cistatin can predict the optimal withdrawal time of continuous renal replacement therapy (CRRT) in patients with acute kidney injury. The study will involve patients who are naive to renal injury and are admitted to various intensive care units. By measuring c-cistatin levels from the initiation to the discontinuation of CRRT, researchers hope to identify a reliable biomarker for weaning off renal support.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with acute kidney injury who require CRRT.

Not a fit: Patients with chronic kidney disease, those requiring renal replacement therapy for reasons other than acute kidney injury, or those with certain exclusions like ongoing CRRT or neoplastic disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved timing for discontinuing renal support in acute kidney injury patients, potentially enhancing recovery outcomes.

How similar studies have performed: While this approach is observational and may have been explored in other contexts, the specific use of c-cistatin as a predictive marker for weaning from CRRT in acute kidney injury is relatively novel.

Eligibility criteria

Inclusion Criteria:

* age ≥ 18 years;
* diagnosis of acute kidney injury (defined according to KDIGO 2012 criteria)
* need for support with CRRT according to the indications of the nephrologist consultants and Clinical Practice
* Obtaining informed consent

Exclusion Criteria:

* CRRT already ongoing (in another department not participating in the study) at the time of transfer/admission to intensive care;
* need for RRT (any type and modality) in the 14 days prior to enrolment;
* diagnosis of AKD/CKD/ESRF on admission;
* Discontinuation of CRRT under conditions that do not comply with the criteria established by the study;
* Need for CRRT not associated with AKI condition (e.g. elimination of toxicants);
* pregnant women;
* presence of known thyreopathy
* Continuous use of corticosteroids
* patient with known neoplastic disease.

Where this trial is running

Bologna and 1 other locations

• IRCCS Azienda Ospedaliero-Universitaria di Bologna - Anestesia e Terapia Intensiva nelle emergenze locali, regionali e nazionale e nella chirurgia addominale maggiore — Bologna, Italy (RECRUITING)
• IRCCS Azienda Ospedaliero-Universitaria di Bologna -Anestesiologia e terapia intensiva polivalente — Bologna, Italy (RECRUITING)

Study contacts

• Principal investigator: Francesco Marino, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Francesco Marino, MD

Conditions: Acute Kidney Injury, C cistatin, acute kidney injury, CRRT, weaning